Skip to main content
SpringerLink
Log in

Publication biases and phase II trials investigating anticancer targeted therapies

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The aim of this study was to determine which parameter may affect impact factor (IF) of journals publishing reports of phase II trial (P2T) investigating molecular targeted therapies (MTT). We reviewed 74 reports of P2Ts investigating MTT (imatinib, n = 55; sorafenib, n = 11; sunitinib, n = 5; dasatinib, n = 3) issued between 1/2002 and 6/2008. As a result, we found that the final result of the trial itself was the most important parameter that was related to IF, as the median-IF was significantly lower for negative trials than for positive trials (2.71 vs 6.14, p = 0.004).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Krzyzanowska MK, Pintillie M, Tannock IF (2003) Factors associated with failure to publish large randomized trials presented at an Oncology Meeting. JAMA 290:495–501. doi:10.1001/jama.290.4.495

    Article  PubMed  Google Scholar 

  2. Hall R, De Antueno C, Webber A (2007) Publication bias in medical literature: a review by a Canadian Research Ethics Board. Can J Anaesth 54:380–388

    Article  PubMed  Google Scholar 

  3. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187. doi:10.1056/NEJMra044389

    Article  CAS  PubMed  Google Scholar 

  4. Dent S, Zee B, Dancey J, Hanauske A, Wanders J, Einsenhauer E (2001) Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol 19:785–791

    CAS  PubMed  Google Scholar 

  5. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512. doi:10.1200/JCO.2005.03.6723

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, Centre Oscar Lambret, 3 rue Combemale, 59020, Lille, France

    Nicolas Penel & Antoine Adenis

Authors
  1. Nicolas Penel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoine Adenis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antoine Adenis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Penel, N., Adenis, A. Publication biases and phase II trials investigating anticancer targeted therapies. Invest New Drugs 27, 287–288 (2009). https://doi.org/10.1007/s10637-008-9186-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-008-9186-4

Keywords

Search

Navigation